# MARKET_RESEARCH_LOG_2026-08-27

> Production GenGe V3.1.1 hourly scan handoff. Repository `main` remains the source of truth. This log records completed production artifacts and is not an automatic trading instruction.

## 2026-08-27 00:10 CST — hourly opportunity + holdings risk refresh

- Production contract re-read from current main: `GEN_GE_V3_1_1_PRODUCTION`; LOW/INVALID valuation confidence -> HOLD_REVIEW; Hard Gate FAIL -> EXIT; no V3.2 sell-confirmation rules imported.
- Holdings universe rebuilt exclusively from `CURRENT_HOLDINGS.md`: `603369 今世缘`, `001316 润贝航科`, `600276 恒瑞医药`, `600406 国电南瑞`.
- `603658 安图生物`: RESEEN / NO MATERIAL CHANGE; WAIT; Formal BUY NO. Existing H1 earnings/cash-flow deterioration, slower demand/pricing-pressure evidence, incomplete moat audit and incomplete Bear/Base/Bull reverse valuation remain controlling. Exact accepted execution-grade close remained 34.17 CNY on 2026-08-25.
- Holdings: 今世缘 HOLD_REVIEW / NO ADD; 润贝航科 HOLD_REVIEW; 恒瑞医药 HOLD_REVIEW; 国电南瑞 HOLD_REVIEW. New REDUCE/EXIT: NONE. New thesis invalidation: NONE.
- Production/CI refresh found no confirmed chain failure. Notification threshold not met.

## 2026-08-27 01:08 CST — hourly opportunity + holdings-risk refresh

- Re-read repository truth sources and rebuilt holdings only from `CURRENT_HOLDINGS.md`.
- `603658 安图生物`: RESEEN / NO MATERIAL CHANGE; WAIT; Formal BUY NO; valuation confidence INVALID. Existing blockers unchanged; no new execution-eligible A1/A2.
- `001316 润贝航科`: exact 2026-08-26 close resolved to 26.69 CNY; this is `PRICE_ONLY_CHANGE / PRICE_FRESHNESS_RESOLVED`, not a rating/action change. Insider/shareholder reduction plan remains a governance/supply-overhang watch; strong 2026H1 operating growth still prevents REDUCE/EXIT.
- `603369 今世缘`: HOLD_REVIEW / NO ADD; accepted 2026-08-26 close 28.10 CNY.
- `600276 恒瑞医药`: HOLD_REVIEW; accepted 2026-08-26 close 46.74 CNY.
- `600406 国电南瑞`: HOLD_REVIEW; accepted 2026-08-26 close 23.42 CNY; H1 cash-conversion/margin deterioration remains under review.
- New REDUCE/EXIT: NONE. New hard-thesis invalidation: NONE. Notification threshold not met.

## 2026-08-27 02:05 CST — hourly opportunity + holdings-risk refresh

### Data cutoff / reproducibility

- Re-read current `main` truth sources before decisioning, including `AGENTS.md`, the production V3.1.1 contract reflected in current logs/handoff, `CURRENT_MARKET_RESEARCH.md`, `RESEARCH_QUEUE.md`, `MODEL_EVOLUTION_LOG.md`, `V31_CANDIDATE_LEDGER.md`, `CURRENT_HOLDINGS.md`, and `V31_DURABLE_HANDOFF.md`.
- Latest completed A-share trading session remains 2026-08-26; no new trading session occurred after the previous hourly refresh.
- Holdings universe rebuilt exclusively from `CURRENT_HOLDINGS.md`: `603369 今世缘`, `001316 润贝航科`, `600276 恒瑞医药`, `600406 国电南瑞`.
- Public post-close filing/event refresh cutoff: 2026-08-27 02:05 CST. Fresh-data invariant remains mandatory; stale/unverified price cannot create Formal BUY/ADD or a price-dependent REDUCE.

### Opportunity / ledger delta

- `603658 安图生物`: **RESEEN / NO MATERIAL CHANGE**. Tier `WAIT`; Formal BUY `NO`; production action `HOLD_REVIEW`; valuation confidence remains INVALID.
- No new post-01:08 filing/event evidence changes the controlling thesis: company-confirmed slower IVD demand growth, homogeneous competition and procurement-price pressure; 2026H1 profit/cash-flow deterioration; unresolved moat strength under that regime; incomplete normalized earnings and Bear/Base/Bull reverse valuation.
- Exact accepted execution-grade close remains **34.17 CNY on 2026-08-25**. Public evidence for 2026-08-26 still does not establish the second independently accepted exact 15:00 close required by the production freshness rule. Observed entry band remains **33.58–34.15 CNY** but cannot override fundamental/confidence blockers.
- Ledger persisted with `last_seen=2026-08-27 02:05 CST`, `seen_count=17`, run_id `hourly-20260827-0205`.
- No NEW / UPGRADED / DOWNGRADED / INVALIDATED execution-eligible candidate; no new A1/A2; no Formal BUY/ADD.

### Holdings risk delta

- `603369 今世缘`: **HOLD_REVIEW / NO ADD**. Accepted 2026-08-26 close 28.10 CNY. Structural baijiu demand/channel pressure remains the burden of proof; no new post-close filing/event establishes a fresh REDUCE/EXIT trigger.
- `001316 润贝航科`: **HOLD_REVIEW**, not REDUCE. Accepted 2026-08-26 close 26.69 CNY. The management/shareholder reduction plan remains a governance/supply-overhang watch, but 2026H1 revenue/profit/cash-flow growth remains strong and no new evidence links the plan to order, margin, cash-conversion or management-continuity deterioration.
- `600276 恒瑞医药`: **HOLD_REVIEW**. Accepted 2026-08-26 close 46.74 CNY. No new post-01:08 pipeline, governance, customer or moat evidence creates REDUCE/EXIT.
- `600406 国电南瑞`: **HOLD_REVIEW**. Accepted 2026-08-26 close 23.42 CNY. H1 cash-conversion and margin deterioration remain the active review issue; no new order/moat evidence escalates to REDUCE/EXIT.
- **New REDUCE/EXIT:** NONE. **New hard-thesis invalidation:** NONE.

### Production / data-source health

- Public post-close refresh returned no evidence of a production-chain or data-source failure that would invalidate the scan. Fresh-data fail-closed behavior remains active for unresolved exact-price evidence.
- No model threshold, valuation rule, holdings universe, or production policy was changed in this run.

### Notification decision

- **NO USER NOTIFICATION.** No new A1/A2 entered an executable buy range; no important new name entered `CURRENT DEEP RESEARCH QUEUE`; no material candidate rating/valuation/entry-band change; no holding REDUCE/EXIT or hard-thesis invalidation; no confirmed production/data/CI failure making the scan unreliable.

## 2026-08-27 03:09 CST — hourly opportunity + holdings-risk refresh

### Data cutoff / reproducibility

- Re-read current `main` truth sources and rebuilt the holding universe exclusively from `CURRENT_HOLDINGS.md`: `603369 今世缘`, `001316 润贝航科`, `600276 恒瑞医药`, `600406 国电南瑞`.
- Latest completed A-share trading session remains 2026-08-26; this run is a post-close filing/news refresh, not a new trading-session price scan.
- Fresh public-event cutoff: 2026-08-27 03:09 CST. Fresh-data invariant remains controlling.

### Opportunity / ledger delta

- `603658 安图生物`: **RESEEN / NO MATERIAL CHANGE**. Tier `WAIT`; Formal BUY `NO`; valuation confidence `INVALID`. Existing slower-demand/pricing-pressure evidence, weakened H1 earnings/cash conversion, unresolved moat audit, and incomplete normalized Bear/Base/Bull valuation remain the blockers.
- No NEW / UPGRADED / DOWNGRADED / INVALIDATED execution-eligible candidate and no new A1/A2 entered an executable buy range.
- Ledger persisted with `last_seen=2026-08-27 03:09 CST`, `seen_count=18`, run_id `hourly-20260827-0309`.

### Holdings risk delta

- `603369 今世缘`: **HOLD_REVIEW / NO ADD**. No fresh post-02:05 filing/event establishes a REDUCE/EXIT trigger.
- `001316 润贝航科`: **HOLD_REVIEW**, not REDUCE. The 2026-08-26 evening management/shareholder reduction plan is already incorporated; public post-close refresh adds no new evidence of order, margin, cash-conversion or management-continuity deterioration. Accepted 2026-08-26 close remains 26.69 CNY.
- `600276 恒瑞医药`: **HOLD_REVIEW**. No fresh post-02:05 pipeline/governance/customer/moat event creates REDUCE/EXIT.
- `600406 国电南瑞`: **HOLD_REVIEW**. H1 cash-conversion/margin deterioration remains the active issue; no fresh post-02:05 evidence escalates it to REDUCE/EXIT.
- **New REDUCE/EXIT:** NONE. **New hard-thesis invalidation:** NONE.

### Production / data-source health

- No confirmed production-chain, data-source or CI failure was found that would make the scan unreliable.
- No model threshold, valuation rule or production policy changed.

### Notification decision

- **NO USER NOTIFICATION.** None of the configured notification thresholds was met.

## 2026-08-27 04:09 CST — hourly opportunity + holdings-risk refresh

### Data cutoff / reproducibility

- Re-read current `main` truth sources, `CURRENT_HOLDINGS.md`, `V31_CANDIDATE_LEDGER.md`, market/research handoffs and frozen V3.1/V3.1.1 implementation before decisioning.
- Latest completed A-share trading session remains 2026-08-26. This is an overnight filing/news and production-health refresh; no new trading session occurred.
- Holdings universe rebuilt exclusively from `CURRENT_HOLDINGS.md`: `603369 今世缘`, `001316 润贝航科`, `600276 恒瑞医药`, `600406 国电南瑞`.
- Public filing/news cutoff: 2026-08-27 04:09 CST. Exchange/CNINFO refresh found no new post-03:09 material filing for the four holdings or `603658 安图生物` that changes the investment decision.

### Opportunity / ledger delta

- `603658 安图生物`: **RESEEN / NO MATERIAL CHANGE**. Tier `WAIT`; Formal BUY `NO`; production action `HOLD_REVIEW`; valuation confidence remains `INVALID`. Existing demand/pricing, H1 cash-conversion, moat and normalized valuation blockers remain controlling.
- Ledger persisted with `last_seen=2026-08-27 04:09 CST`, `seen_count=19`, run_id `hourly-20260827-0409`.
- No NEW / UPGRADED / DOWNGRADED / INVALIDATED execution-eligible candidate; no new A1/A2; no Formal BUY/ADD.

### Holdings risk delta

- `603369 今世缘`: **HOLD_REVIEW / NO ADD**; no new REDUCE/EXIT trigger.
- `001316 润贝航科`: **HOLD_REVIEW**; already-known management/shareholder reduction overhang remains under review; no new operating/thesis-break evidence.
- `600276 恒瑞医药`: **HOLD_REVIEW**; no new pipeline/governance/customer/moat event creates REDUCE/EXIT.
- `600406 国电南瑞`: **HOLD_REVIEW**; H1 cash-conversion/margin deterioration remains under review; no new escalation evidence.
- **New REDUCE/EXIT:** NONE. **New hard-thesis invalidation:** NONE.

### Production / CI health — NEW FAILURE DETECTED

- Main commit `f00029174f32ec58d261ff9c14446c52cac8ba13` triggered downstream run `33008318876` (`GenGe Postscan Research Pipeline`) and run `33008318852` (`GenGe V3.1.1 Every-Industry Research`) at about 04:02 CST; both failed before candidate/valuation production steps.
- Failure is reproducible and isolated to focused tests after the V3.1.1 confidence-gate promotion: **3 failed / 138 passed** in the postscan suite. Failing expectations were two long-term Formal-BUY fixtures that omitted the newly required Round-8/9 confidence evidence, plus one production-scanner test that still expected upstream production decision fields to be reused.
- Because the focused-test step failed, subsequent industry map, valuation routing/execution, Formal BUY review and V3.1.1 production-decision artifact steps were skipped; upload then also failed because those reports did not exist. Therefore the latest downstream automated research artifact is **not complete/reliable for new opportunity discovery**.
- Minimal evidence-backed repair only; **no V3.1/V3.1.1 threshold or trading rule changed**. Commit `a449bcb690f41593172db9deebbb76c9b1f076c9` adds explicit valid confidence evidence to the long-term BUY fixtures. Commit `a1c56a43460c8ccdcc3fe951a92fa49ec6b63b2b` updates the production-scanner regression to enforce the existing authority boundary: exact policy labels are audit metadata; production decisions are recomputed from evidence and upstream decision fields are never reused.
- V3.1.1 parity verification for the repair was triggered and was still in progress at this run cutoff. Until green, treat the automated downstream opportunity chain as **DEGRADED / FAIL-CLOSED**. Manual holdings/news refresh above remains valid; no Formal BUY/ADD may be promoted from the failed downstream runs.

### Notification decision

- **USER NOTIFICATION REQUIRED — production/CI failure.** This meets notification condition (5). There is no new BUY or REDUCE/EXIT; the notification is specifically about degraded automated opportunity-scan reliability and the minimal compatibility fix already pushed.

## 2026-08-27 05:07 CST — hourly opportunity + holdings-risk refresh

### Data cutoff / reproducibility

- Re-read current `main` truth sources and rebuilt the holding universe exclusively from `CURRENT_HOLDINGS.md`: `603369 今世缘`, `001316 润贝航科`, `600276 恒瑞医药`, `600406 国电南瑞`.
- Latest completed A-share trading session remains 2026-08-26. Exchange/CNINFO overnight refresh through 05:07 CST found no new material filing changing the four holdings or `603658 安图生物`; no new session price exists yet.
- Fresh-data invariant remains active. No stale/unverified price can promote Formal BUY/ADD or a price-dependent REDUCE.

### Opportunity / ledger delta

- `603658 安图生物`: **RESEEN / NO MATERIAL CHANGE**. Tier `WAIT`; Formal BUY `NO`; production action `HOLD_REVIEW`; valuation confidence remains `INVALID`. Existing slower-demand/pricing-pressure, weakened H1 earnings/cash conversion, moat and normalized Bear/Base/Bull blockers remain controlling.
- Ledger persisted with `last_seen=2026-08-27 05:07 CST`, `seen_count=20`, run_id `hourly-20260827-0507`.
- No NEW / UPGRADED / DOWNGRADED / INVALIDATED execution-eligible candidate; no new A1/A2; **Formal BUY/ADD = NONE**.

### Holdings risk delta

- `603369 今世缘`: **HOLD_REVIEW / NO ADD**; no fresh REDUCE/EXIT trigger.
- `001316 润贝航科`: **HOLD_REVIEW**; known insider/shareholder reduction overhang remains, with no new evidence of operating-thesis break.
- `600276 恒瑞医药`: **HOLD_REVIEW**; no fresh pipeline/governance/customer/moat event creates REDUCE/EXIT.
- `600406 国电南瑞`: **HOLD_REVIEW**; H1 cash-conversion/margin deterioration remains under review, with no fresh escalation evidence.
- **New REDUCE/EXIT = NONE. New hard-thesis invalidation = NONE.**

### Production / CI health — ROOT CAUSE REFINED + MINIMAL REPAIR

- Latest postscan run `33012470841` progressed through the entire research/valuation/production build. The focused suite is now **141/141 passing**; the prior V3.1.1 fixture/scanner compatibility defect is repaired.
- Final contract validation still failed with `valuation_model_not_executed` and `valuation_diagnostic_not_ready`. Artifact inspection traced both unresolved tokens to `688739`, which is `RESEARCH_ONLY` / not execution eligible. The other long-term rows were also `688xxx` research-only names. Production `production_decision_scan.py` already excludes non-execution-eligible candidates, so the final zero-BUY validator was applying a stricter universe than the production decision authority.
- Defect classification: **PRODUCTION_VALIDATOR_EXECUTION_SCOPE_DRIFT**. This is a contract-scope bug, not evidence that an executable沪A/深A candidate was missing valuation research.
- Minimal repair committed without changing any V3.1/V3.1.1 ranking, valuation, BUY/SELL threshold or research record: added `postscan_contract.py`, which scopes unresolved zero-BUY model gaps to `EXECUTION_ELIGIBLE` rows; added regression tests proving a research-only `688739` gap does not block production while an executable `603658` gap still does; updated the postscan workflow to use that helper and run the regression test.
- Research-only valuation diagnostics remain preserved in artifacts; they are not silently converted to READY. They simply no longer control the executable production contract.
- Full downstream green verification on the new workflow revision is still pending the next valid postscan execution. Until confirmed green, keep automated opportunity discovery **DEGRADED / FAIL-CLOSED**; manual holdings-risk conclusions above remain valid.

### Notification decision

- **USER NOTIFICATION REQUIRED — production/CI condition (5) remains active.** Root cause is now isolated and minimally repaired, but full downstream green proof is still pending. No new BUY, REDUCE or EXIT accompanies this notification.
